Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 3/2017

01-09-2017 | Review

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

Authors: Martin K. Bakht, So Won Oh, Hyewon Youn, Gi Jeong Cheon, Cheol Kwak, Keon Wook Kang

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2017

Login to get access

Abstract

Prostate-specific membrane antigen (PSMA) is an attractive target for both diagnosis and therapy because of its high expression in the vast majority of prostate cancers. Development of small molecules for targeting PSMA is important for molecular imaging and radionuclide therapy of prostate cancer. Recent evidence implies that androgen-deprivation therapy increase PSMA-ligand uptake in some cases. The reported upregulations in PSMA-ligand uptake after exposure to second-generation antiandrogens such as enzalutamide and abiraterone might disturb PSMA-targeted imaging for staging and response monitoring of patients undergoing treatment with antiandrogen-based drugs. On the other hand, second-generation antiandrogens are emerging as potential endoradio-/chemosensitizers. Therefore, the enhancement of the therapeutic efficiency of PSMA-targeted theranostic methods can be listed as a new capability of antiandrogens. In this manuscript, we will present what is currently known about the mechanism of increasing PSMA uptake following exposure to antiandrogens. In addition, we will discuss whether these above-mentioned antiandrogens could play the role of endoradio-/chemosensitizers in combination with the well-established PSMA-targeted methods for pre-targeting of prostate cancer.
Literature
1.
Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866–71.PubMedPubMedCentral
2.
Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget. 2015;29:35542–55.
3.
4.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.CrossRefPubMed
5.
Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–68.PubMedPubMedCentral
6.
Rai BP, Baum R, Patel A, Hughes R, Alonzi R, Lane T, et al. The role PET with 68Gallium (Ga)-labelled prostate-specific membrane antigen (PSMA) in the management of patient with organ confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy. Urology. 2016. doi:10.​1016/​j.​urology.​2015.​12.​048.PubMedCentral
7.
Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101–8.CrossRefPubMed
8.
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281–8.CrossRefPubMed
9.
Rybalov M, Ananias HJ, Hoving HD, van der Poel HG, Rosati S, de Jong IJ. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci. 2014;15:6046–61.CrossRefPubMedPubMedCentral
10.
11.
Lutje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388–401.CrossRefPubMedPubMedCentral
12.
Vargas H, Grimm J, Donati FO, Sala E, Hricak H. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol. 2015;25:1294–302.CrossRefPubMedPubMedCentral
13.
Vallabhajosula S, Jhanwar Y, Tagawa S, Epstein J, Babich J, Youn T, et al. 99m Tc-MIP-1404 Planar and SPECT scan: Imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression. J Nucl Med 2016:57:1541–1.
14.
Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1794–800.CrossRefPubMedPubMedCentral
15.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.CrossRefPubMed
16.
Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, et al. Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules. 2015;20:14860–78.CrossRefPubMed
17.
Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34–41.CrossRefPubMed
18.
Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, et al. [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):987–8.CrossRefPubMed
19.
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.CrossRefPubMed
20.
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51.CrossRefPubMed
21.
Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74.CrossRefPubMedPubMedCentral
22.
Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a novel probe targeting prostate specific membrane antigen for Imaging and Therapy (68Ga-PSMA I&T). J Nucl Med. 2015;56:855–61.CrossRefPubMedPubMedCentral
23.
Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83.CrossRefPubMed
24.
Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–8.CrossRefPubMed
25.
Dost RJ, Glaudemans AW, Breeuwsma AJ, de Jong IJ. Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:41–7.CrossRef
26.
Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578–82.CrossRefPubMedPubMedCentral
27.
Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75:242–54.CrossRefPubMed
28.
DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate. 2016;76:325–34.CrossRefPubMed
29.
Meller B, Bremmer F, Sahlmann C, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:1–11.CrossRef
30.
O’Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1998;1443:113–27.CrossRefPubMed
31.
32.
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–11.PubMed
33.
Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urol. 1996;48:326–34.CrossRefPubMed
34.
Good D, Schwarzenberger P, Eastham JA, Rhoads RE, Hunt JD, Collins M, et al. Cloning and characterization of the prostate-specific membrane antigen promoter. J Cell Biochem. 1999;74:395–405.CrossRefPubMed
35.
Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O’Keefe DS, et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics. 2001;73:243–54.CrossRefPubMed
36.
Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene. 2002;285:247–56.CrossRefPubMed
37.
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17:443–54.CrossRefPubMedPubMedCentral
38.
DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E. In vivo efficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer. Cancer Res. 2015;75:1685.CrossRef
39.
40.
Ammannagari N, George S. Anti-androgen therapies for prostate cancer: a focused review. Am J Hema Oncl. 2015;11:15–9.
41.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.CrossRefPubMedPubMedCentral
42.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefPubMed
43.
Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40:163–6.CrossRef
44.
45.
Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [68Ga] PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.CrossRefPubMed
46.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.CrossRefPubMed
47.
Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293–8.CrossRefPubMed
48.
Wilbur DS, Chyan M-K, Hamlin D, Balkin E. In vivo comparison of two anti-PSMA mAb Fab’ conjugates containing branched-chain PEG derivatives with Fab’ and F(ab’)2. J Nucl Med. 2012;53:1545.
49.
Behnam Azad B, Banerjee SR, Pullambhatla M, Lacerda S, Foss CA, Wang Y, et al. Evaluation of a PSMA-targeted BNF nanoparticle construct. Nanoscale. 2015;7:4432–42.CrossRefPubMed
50.
Moon S-H, Yang BY, Kim YJ, Hong MK, Lee Y-S, Lee DS, et al. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA). Nanomed Nanotech Biol Med. 2016;12:871–9.CrossRef
51.
DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E. Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts. Prostate. 2015;75:303–13.CrossRefPubMed
52.
Paximadis P, Najy AJ, Snyder M, Kim HR. The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma. Prostate. 2016;76:534–43.CrossRefPubMed
53.
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46.CrossRefPubMedPubMedCentral
54.
Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2014;12:312–6.CrossRefPubMed
55.
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio S, Menna C, et al. 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42:1276–83.CrossRefPubMed
56.
Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012;2:985–4.CrossRefPubMedPubMedCentral
57.
Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:5–10.CrossRefPubMedCentral
58.
Tolmachev V, Malmberg J, Estrada S, Eriksson O, Orlova A. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. Int J Oncol. 2014;44:1998–2008.PubMed
59.
Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, et al. A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. J Nucl Med. 2015;56:1094–9.CrossRefPubMed
60.
Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011;52:1087–93.CrossRefPubMed
61.
Chatalic KS, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JM, Franssen GM, Clahsen-van Groningen MC, et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016;6:849–61.CrossRefPubMedPubMedCentral
62.
Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, et al. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004;10:1051–8.CrossRefPubMed
63.
Cheng WS, Kraaij R, Nilsson B, van der Weel L, de Ridder CM, Tötterman TH, et al. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther. 2004;10:355–64.CrossRefPubMed
64.
Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M. Development of gene therapy using prostate‐specific membrane antigen promoter/enhancer with Cre recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jap J Cancer Res. 2002;93:1154–63.CrossRef
65.
Zhao W, Xu Y, Kong D, Liu R, Zhang Z, Jin C, et al. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer. Urol Oncol. 2009;27:539–66.CrossRefPubMed
66.
Zhao FJ, Zhang S, Yu ZM, Xia SJ, Li H. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosylltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. Prostate Cancer Prostatic Dis. 2009;12:166–71.CrossRefPubMed
67.
Zeng H, Wei Q, Huang R, Chen N, Dong Q, Yang Y, et al. Recombinant adenovirus mediated prostate‐specific enzyme pro‐drug gene therapy regulated by prostate‐specific membrane antigen (PSMA) enhancer/promoter. J Androl. 2007;28:827–35.CrossRefPubMed
Metadata
Title
Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges
Authors
Martin K. Bakht
So Won Oh
Hyewon Youn
Gi Jeong Cheon
Cheol Kwak
Keon Wook Kang
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2017
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0439-4

Other articles of this Issue 3/2017

Nuclear Medicine and Molecular Imaging 3/2017 Go to the issue

Original Article

Difference in F-18 FDG Uptake After Esophagogastroduodenoscopy and Colonoscopy in Healthy Sedated Subjects

Case Report

Incidentally Detected Small Intestine Intussusception Caused by Primary Small Intestine Carcinoma on 18F-FDG PET/CT

Interesting Image

68Gallium-Arginine-Glycine-Aspartic Acid and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull

Original Article

Clinical Significance of Incidental Focal 18F-FDG Uptake in the Spinal Cord of Patients with Cancer

Case Report

Bilateral Renal Metastasis of Hürthle Cell Thyroid Cancer with Discordant Uptake Between I-131 Sodium Iodide and F-18 FDG

Original Article

Prognostic Value of Tumor-to-Blood Standardized Uptake Ratio in Patients with Resectable Non-Small-Cell Lung Cancer